Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
PALI
Valuation N/A
PALISADE BIO, INC.
Price$1.45
Model IV—
P/IV—
Market implies +84.6%/yr
vs model +15.0% · above model
PASG
Valuation N/A
Passage BIO, Inc.
Price$3.78
Model IV—
P/IV—
Limited data — see page
PCVX
Valuation N/A
Vaxcyte, Inc.
Price$65.02
Model IV—
P/IV—
Limited data — see page
PHGE
Valuation N/A
BiomX Inc.
Price$0.29
Model IV—
P/IV—
Limited data — see page
PLUR
Valuation N/A
Pluri Inc.
Price$1.00
Model IV—
P/IV—
Market implies +13.1%/yr
vs model +15.0% · in line
PLX
Valuation N/A
Protalix BioTherapeutics, Inc.
Price$2.70
Model IV—
P/IV—
Market implies +17.9%/yr
PMCB
Valuation N/A
PharmaCyte Biotech, Inc.
Price$0.40
Model IV—
P/IV—
Limited data — see page
PRME
Valuation N/A
Prime Medicine, Inc.
Price$3.58
Model IV—
P/IV—
Market implies +76.0%/yr
PROK
Valuation N/A
PROKIDNEY CORP.
Price$1.66
Model IV—
P/IV—
Limited data — see page
PTHS
Deeply overvalued
Pelthos Therapeutics Inc.
Price$20.50
Model IV$8.93
P/IV2.64
Premium +130%
Return to IV: -56.5%
Market implies +9.4%/yr
vs model +15.0% · below model
QGEN
Fairly valued
QIAGEN N.V.
Price$44.53
Model IV$41.36
P/IV1.06
Premium +8%
Return to IV: -7.1%
Market implies +6.3%/yr
vs model +6.5% · in line
QNCX
Valuation N/A
Quince Therapeutics, Inc.
Price$29.36
Model IV—
P/IV—
Limited data — see page
REPL
Valuation N/A
Replimune Group, Inc.
Price$13.04
Model IV—
P/IV—
Limited data — see page
RGEN
Valuation N/A
REPLIGEN CORP
Price$163.84
Model IV—
P/IV—
Limited data — see page
RGNX
Valuation N/A
REGENXBIO Inc.
Price$8.09
Model IV—
P/IV—
Market implies +56.3%/yr
vs model +2.0% · above model
RLAY
Valuation N/A
Relay Therapeutics, Inc.
Price$17.41
Model IV—
P/IV—
Market implies +63.1%/yr
vs model +50.0% · above model
RVMD
Valuation N/A
Revolution Medicines, Inc.
Price$188.12
Model IV—
P/IV—
Market implies +124.7%/yr
vs model +15.0% · above model
RVMDW
Valuation N/A
Revolution Medicines, Inc.
Price$9.44
Model IV—
P/IV—
Market implies +66.8%/yr
RXRX
Valuation N/A
RECURSION PHARMACEUTICALS, INC.
Price$3.95
Model IV—
P/IV—
Market implies +38.8%/yr
vs model +50.0% · below model
SABS
Valuation N/A
SAB Biotherapeutics, Inc.
Price$2.89
Model IV—
P/IV—
Market implies +64.4%/yr
SABSW
Valuation N/A
SAB Biotherapeutics, Inc.
Price$0.01
Model IV—
P/IV—
Market implies -7.5%/yr
SANA
Valuation N/A
Sana Biotechnology, Inc.
Price$2.79
Model IV—
P/IV—
Limited data — see page
SCLX
Valuation N/A
Scilex Holding Co
Price$2.96
Model IV—
P/IV—
Limited data — see page
SCLXW
Valuation N/A
Scilex Holding Co
Price$0.09
Model IV—
P/IV—
Market implies +43.1%/yr
SCNI
Valuation N/A
Scinai Immunotherapeutics Ltd.
Price$1.21
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
SLDB
Valuation N/A
Solid Biosciences Inc.
Price$6.82
Model IV—
P/IV—
Market implies +54.6%/yr
SLXN
Valuation N/A
Silexion Therapeutics Corp
Price$0.23
Model IV—
P/IV—
Limited data — see page
SLXNW
Valuation N/A
Silexion Therapeutics Corp
Price$0.01
Model IV—
P/IV—
Limited data — see page
SNTI
Valuation N/A
Senti Biosciences Holdings, Inc.
Price$0.32
Model IV—
P/IV—
Market implies +98.0%/yr
vs model +2.0% · above model
SRRK
Valuation N/A
Scholar Rock Holding Corp
Price$42.20
Model IV—
P/IV—
Market implies +66.5%/yr
vs model +15.0% · above model
SRZN
Valuation N/A
Surrozen, Inc./DE
Price$27.97
Model IV—
P/IV—
Limited data — see page
STRO
Valuation N/A
SUTRO BIOPHARMA, INC.
Price$15.32
Model IV—
P/IV—
Market implies -5.6%/yr
vs model +13.4% · below model
TARA
Valuation N/A
Protara Therapeutics, Inc.
Price$2.65
Model IV—
P/IV—
Limited data — see page
TARS
Undervalued
Tarsus Pharmaceuticals, Inc.
Price$72.22
Model IV$102.71
P/IV0.72
Discount 30%
Return to IV: +42.2%
Market implies -7.3%/yr
vs model +50.0% · below model
TCRX
Valuation N/A
TScan Therapeutics, Inc.
Price$0.23
Model IV—
P/IV—
Market implies +56.3%/yr
vs model +2.0% · above model
TECH
Deeply overvalued
BIO-TECHNE Corp
Price$72.45
Model IV$20.97
P/IV2.46
Premium +245%
Return to IV: -71.1%
Market implies +23.9%/yr
vs model +7.9% · above model
TECX
Valuation N/A
Tectonic Therapeutic, Inc.
Price$22.75
Model IV—
P/IV—
Limited data — see page
TIL
Valuation N/A
Instil Bio, Inc.
Price$6.56
Model IV—
P/IV—
Limited data — see page
TNYA
Valuation N/A
Tenaya Therapeutics, Inc.
Price$0.54
Model IV—
P/IV—
Limited data — see page
TSHA
Valuation N/A
Taysha Gene Therapies, Inc.
Price$4.43
Model IV—
P/IV—
Market implies +81.5%/yr
vs model +15.0% · above model
TVGN
Valuation N/A
Tevogen Inc.
Price$7.06
Model IV—
P/IV—
Limited data — see page
TWST
Valuation N/A
Twist Bioscience Corp
Price$152.05
Model IV—
P/IV—
Market implies +52.8%/yr
vs model +29.9% · above model
VACH
Valuation N/A
VACH
Price$17.11
Model IV—
P/IV—
Limited data — see page
VALN
Valuation N/A
Valneva SE
Price$5.69
Model IV—
P/IV—
Market implies +23.1%/yr
VCEL
Deeply overvalued
Vericel Corp
Price$40.05
Model IV$13.34
P/IV2.91
Premium +200%
Return to IV: -66.7%
Market implies +10.3%/yr
vs model +15.3% · below model
VIR
Valuation N/A
Vir Biotechnology, Inc.
Price$11.12
Model IV—
P/IV—
Market implies +60.7%/yr
VIVS
Valuation N/A
VivoSim Labs, INC.
Price$0.18
Model IV—
P/IV—
Market implies -14.1%/yr
vs model +15.0% · below model
VOR
Valuation N/A
Vor Biopharma Inc.
Price$19.13
Model IV—
P/IV—
Limited data — see page
VYGR
Valuation N/A
Voyager Therapeutics, Inc.
Price$2.37
Model IV—
P/IV—
Market implies +30.3%/yr
XFOR
Valuation N/A
X4 Pharmaceuticals, Inc
Price$2.79
Model IV—
P/IV—
Market implies +46.7%/yr
ZURA
Valuation N/A
Zura Bio Ltd
Price$4.13
Model IV—
P/IV—
Limited data — see page